IDO and tolerance to tumors
- 1 January 2004
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 10 (1) , 15-18
- https://doi.org/10.1016/j.molmed.2003.11.003
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenaseNature Medicine, 2003
- Tryptophan Catabolism and Regulation of Adaptive ImmunityThe Journal of Immunology, 2003
- Tolerance, DCs and tryptophan: much ado about IDOTrends in Immunology, 2003
- Tolerogenic Dendritic CellsAnnual Review of Immunology, 2003
- Natural versus adaptive regulatory T cellsNature Reviews Immunology, 2003
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell ResponsesThe Journal of Immunology, 2002
- Cross-presentation of tumor antigens by bone marrow–derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progressionBlood, 2001
- Prevention of Allogeneic Fetal Rejection by Tryptophan CatabolismScience, 1998
- Relationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolismThe FASEB Journal, 1991